Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...
Jim Cramer Prefers Cardinal Health (CAH) Over Cencora
Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against ...
Cardinal Health, Inc. (NYSE:CAH) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, ...
Bank of America Securities Reaffirms Their Buy Rating on Cardinal Health (CAH)
Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company’s shares ...
Cardinal Health price target raised to $150 from $144 at TD Cowen
TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $150 from $144 and keeps a Buy rating on the shares. The firm said they ...
Cardinal Health (NYSE:CAH) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...
Zacks.com on MSN1d
Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...
Cardinal Health may raise prices to offset potential tariffs
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It?
According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' ...
bovnews2d
Cardinal Health Inc (CAH) Stock: Beyond the Surface of Its Performance?
Cardinal Health Inc (CAH) stock saw a decline, ending the day at $127.73 which represents a decrease of $-3.00 or -2.29% from the prior close of $130.73. The stock opened at $130.84 and touched a low ...
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges
Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...